We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
ClinicalTrials.gov will be expanded to include a results database in addition to the existing trial registry if a bill introduced in the Senate passes.
With the Democrats taking control of the Senate, the healthcare agenda will likely focus on increasing the availability of generics in the market, improved drug safety and the role of trade policy in protecting domestic pharmaceuticals, according to industry observers.
A panel of drug industry representatives presented their views on the effects of reverse-payment deals before federal lawmakers at a Senate hearing called to consider proposed legislation that could stop the practice of paying generic drug companies to limit market competition.
Following debate Dec. 12, the New Zealand Parliament voted 61-60 to forward legislation on a trans-Tasman regulatory scheme for therapeutic products to a select committee for further scrutiny.
The House has passed a bill that would extend federal funding for research on stem cells beyond the preexisting cell lines that the Bush administration approved funding for in August 2001. The bill now goes to the Senate for consideration.
In its first major announcement since the midterm elections gave control of the next Congress to the Democrats, the FDA outlined what it believes should be the priorities to improve drug safety without sacrificing innovation. Read More